Pilot trial examines lenalidomide and azacitidine with radiotherapy for treating plasmacytoma, suggesting potential therapeutic benefits.
Key Points
The aim is to assess the safety and efficacy of lenalidomide and oral azacitidine combined with radiotherapy in treating newly diagnosed and relapsed plasmacytoma.
Pilot trial design to evaluate the intervention in patients with plasmacytoma.
Participants included those with newly diagnosed and relapsed conditions.
Combining two medications with radiotherapy as treatment approach.
The trial identifies trends in response rates to the combined treatment.
Data collected suggests improvements in patient outcomes, requiring further investigation.